jumbo phages have unique
biological properties of high
potential to develop novel
technologies targeting top priority AMR pathogens
News & PRess
> OCT '24
patrick guye joins Kinzbio
Kinzbio announces the appointment of its first iNED
We are excited to announce that Patrick Guye PhD/MBA has assumed the role of Independent Non-Executive Director at Kinzbio. His knack for cultivating growth through strategic partnerships in therapeutic, consumer and B2B arenas positions us at the forefront of innovation and commercial success.
​​
Dr. Guye joins the company with a robust background in microbiology and strategic business management, poised to drive Kinzbio's growth and expansion during this pivotal time. His deep expertise in infection biology, extensive experience in therapeutic development and biomedical product management, coupled with a proven track record of guiding startups to success, align perfectly with Kinzbio’s ambitious goals.
​
​
​
​
unleashing the potential of
Jumbo phages
together
Kinzbio fosters collaborations and partnerships with pharma leaders, clinical organizations, academic labs and funding agencies to help the company to accelerate the development of its jumbo phage platform and pipeline.
Kinzbio has an open communication channel with and is always seeking to hear from industry partners and funding institutions interested in joining efforts to keep developing applications based on the biology of jumbo phages.
BE IN
TOUCH
Please fill your contact details below:
Phage technologies for a
healthier world
ANtimicrobial
resistance is one
of the major global
health issues that
humanity is facing
every year millions
of lives are lost and
billions are spent in
prevention and
treatment of AMR
phages are natural
bacterial killers
that can be used to
combat AMR pathogens
